stockrow
Saturday 7 November 2026
Export XFOR’s income statement to Excel — free account
X4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.
- Revenue
- +63.1%
- EPS
- +76.9%
- Free cash flow
- +27.5%
- Total debt
- +1.24%
Quarter to September 2026, against a year earlier
3.15
0.08
+2.61%
Follow XFOR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.82 | 57.86 | 37.23 | 21.63 | |
P/FCF ratio |
10.54 | 59.10 | 37.02 | 15.56 | |
P/Operating CF |
(10.90) | (26.61) | (28.38) | (18.18) | |
P/B ratio |
0.91 | 3.10 | 3.80 | 2.64 | |
Price to Tangible BV |
1.06 | 3.67 | 4.72 | 3.38 | |
EV/Sales |
(0.19) | 40.51 | 29.00 | 15.15 | |
EV/EBITDA |
0.08 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.08 | (3.93) | (5.49) | (3.38) | |
EV/FCF |
(0.42) | 41.38 | 28.84 | 10.90 | |
Quick Ratio |
9.84 | 9.88 | 10.84 | 12.62 | |
Current Ratio |
10.16 | 10.18 | 11.30 | 13.22 | |
Net Debt/EBITDA |
7.53 | 7.83 | 8.52 | 5.63 | |
Debt/Assets |
26.27% | 28.31% | 30.33% | 33.22% | |
Debt/Equity |
0.41 | 0.45 | 0.49 | 0.55 | |
Asset Turnover |
0.16 | 0.05 | 0.09 | 0.09 | |
Operating CF/Net income |
0.65 | 0.97 | 1.29 | 1.00 | |
Capex/Depreciation |
0.00 | 0.00 | (5.01) | 0.00 | |
Interest Coverage |
(10.84) | (9.52) | (7.57) | (9.11) | |
Research and Development Expense of Revenue |
721.22% | 570.53% | 171.24% | 463.46% | |
Selling, General and Administrative Expense of Revenue |
287.46% | 257.24% | 96.54% | 313.09% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.12 | 0.13 | |
Share Based Compensation of Revenue |
88.43% | 89.11% | 35.04% | 121.67% | |
Graham Net Nets |
0.93 | 0.27 | 0.21 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(108.50%) | (109.93%) | (25.70%) | (23.09%) | |
Free Cash Flow Yield |
9.49% | 1.69% | 2.70% | 6.42% | |
Revenue per Share |
0.06 | 0.02 | 0.07 | 0.02 | |
Operating CF per Share |
(0.37) | (0.16) | (0.16) | (0.16) | |
Capex per Share |
0.00 | 0.00 | (0.04) | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.16) | (0.20) | (0.16) | |
Cash per Share |
5.98 | 1.85 | 1.65 | 1.48 | |
Shareholders Equity per Share |
4.40 | 1.33 | 1.23 | 1.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.40 | 1.33 | 1.23 | 1.10 | |
Free Cash Flow |
(15.53) | (19.60) | (25.79) | (20.19) | |
Working Capital |
235.82 | 218.21 | 199.49 | 183.15 | |
Capital Expenditures |
0.00 | — | (5.00) | 0.00 | |
Net Current Asset Value |
157.41 | 140.15 | 121.25 | 105.20 | |
EV/EBIT |
0.08 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.57 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.14 | 1.14 | 1.96 | 1.54 | |
Average Payables |
7.16 | 8.09 | 5.82 | 4.97 | |
Average Inventory |
3.65 | 3.86 | 4.34 | 4.79 | |
Average Assets |
218.45 | 200.15 | 179.12 | 197.69 | |
Average Common Equity |
104.22 | 95.70 | 79.71 | 100.25 |
Columns are period end dates · fundamentals updated 6 Nov 2026